Cite
HARVARD Citation
Bacsur, P. et al. (2022). Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn's disease: results from a multicentre cohort study. Therapeutic advances in gastroenterology. p. . [Online].